Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous

5Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: To report 2 eyes of a patient which developed vitreomacular traction (VMT)1 month after intravitreal bevacizumab (IVB) injection. Materials and Methods: A 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB. Results: Her initial visual acuity (VA) was 0.15 and 0.2 in OD and OS, respectively. Central foveal thickness (CFT) was 568 and 662 μm in OD and OS, respectively, without any sign of VMT. Both eyes responded well initially but developed VMT at 1 month. This time, intravitreal triamcinolone (IVTA) injection was performed. One month after IVTA injection, VMT was released and CFT decreased to 163 and 181 μm in OD and OS, respectively. Six months after IVTA injection, CFT was 163 and 153 μm, and VA was 0.7 and 0.9 in OD and OS, respectively. Conclusion: In eyes with DME and attached posterior vitreous, VMT may develop after IVB injection and increase edema. IVTA injection might be an option to release VMT before considering vitrectomy. © 2013 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Ozsutcu, M., Gulkilik, G., Ayintap, E., Altinisik, M., Demirci, G., & Aras, C. (2013). Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous. Case Reports in Ophthalmology, 4(1), 7–10. https://doi.org/10.1159/000342873

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free